[Skip to Content]
[Skip to Content Landing]
Views 41
Citations 0
Comment & Response
November 30, 2017

Zoledronic Acid Dosing in Patients With Metastatic Breast Cancer

Author Affiliations
  • 1Icahn School of Medicine at Mt Sinai, New York, New York
  • 2Helen F. Graham Cancer Center and Research Institute, Newark, Delaware
JAMA Oncol. Published online November 30, 2017. doi:10.1001/jamaoncol.2017.0789

To the Editor We read the results of the Optimize-2 trial by Hortobagyi et al1 with keen interest. After 9 or more doses of monthly zoledronic acid or pamidronate, 416 women with breast cancer with bone metastases were randomized to receive zoledronic acid once every 4 weeks (4W) or zoledronic acid once every 12 weeks (12W) for 1 year. The results showed that the 12W zoledronic acid was noninferior to 4W zoledronic acid dosing.

First Page Preview View Large
First page PDF preview
First page PDF preview
×